Literature DB >> 21658048

Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies?

Bach-Nga Pham1, Michèle Roussel, Thierry Peyrard, Marylise Beolet, Véronique Jan-Lasserre, Dominique Gien, Maryline Ripaux, Sébastien Bourgouin, Sandrine Kappler-Gratias, Philippe Rouger, Pierre-Yves Le Pennec.   

Abstract

BACKGROUND: Whether anti-D produced by individuals with a weak D phenotype are allo- or autoantibodies remains a matter of debate even though blood transfusion practice is impacted. The aim of our study was to determine the serologic features of anti-D in individuals expressing the most frequent weak D type in Caucasians that are weak D Type 1 or weak D Type 2, to assess whether anti-D were allo- or autoantibodies. STUDY DESIGN AND METHODS: Serologic D typing and molecular analysis enabled the including of 121 weak D Type 1 individuals and 99 weak D Type 2 individuals in our study. Serologic features of anti-D included autologous controls, direct antiglobulin test, elution, and titration of anti-D before and after adsorption of serum on autologous red blood cells (RBCs).
RESULTS: Serologic D typing showed a variable reactivity of RBCs expressing weak D Type 1 or weak D Type 2 (4+ to 0). Anti-D was identified in six weak D Type 1 and six weak D Type 2 individuals, respectively. The serologic data were in favor of autoantibodies.
CONCLUSION: A complete anti-D investigation in individuals with a D variant (weak D or partial D identified by molecular analysis) should be systematically performed before any valid conclusion on the nature of the antibody. Transfusing weak D Type 1 or weak D Type 2 patients with D+ RBC units should be recommended. Weak D Type 1 or weak D Type 2 pregnant women do not need anti-D immunoprophylaxis.
© 2011 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21658048     DOI: 10.1111/j.1537-2995.2011.03207.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  11 in total

1.  Weak D in the Tunisian population.

Authors:  Mouna Ouchari; Houda Romdhane; Taher Chakroun; Saida Abdelkefi; Batoul Houissa; Slama Hmida; Saloua Jemni Yacoub
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  RHD and RHCE molecular analysis in weak D blood donors and in patients with Rh antibodies against their own corresponding Rh antigen.

Authors:  Thamy C Souza Silva; Bruno R Cruz; Sidneia S Costa; Akemi K Chiba; Melca M O Barros; Dante M Langhi; José O Bordin
Journal:  Blood Transfus       Date:  2020-07       Impact factor: 3.443

3.  It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Authors:  S Gerald Sandler; Willy A Flegel; Connie M Westhoff; Gregory A Denomme; Meghan Delaney; Margaret A Keller; Susan T Johnson; Louis Katz; John T Queenan; Ralph R Vassallo; Clayton D Simon
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

4.  Phasing-in RHD genotyping.

Authors:  Willy A Flegel; Susan D Roseff; Ashok Tholpady
Journal:  Arch Pathol Lab Med       Date:  2014-05       Impact factor: 5.534

5.  Strategies to identify candidates for D variant genotyping.

Authors:  Xunda Luo; Margaret A Keller; Ian James; Michelle Grant; Shiguang Liu; Kellie Simmons Massey; Andrew Czulewicz; Sandra Nance; Yanhua Li
Journal:  Blood Transfus       Date:  2017-04-05       Impact factor: 3.443

6.  Allo- and autoanti-D in weak D types and in partial D.

Authors:  Willy A Flegel; Gregory A Denomme
Journal:  Transfusion       Date:  2012-09       Impact factor: 3.157

7.  Variant RHD Types in Brazilians With Discrepancies in RhD Typing.

Authors:  Fernanda Carolina Alves Campos; Mariza Aparecida Mota; Maria Giselda Aravechia; Kelyan Bertani Torres; Carolina Bonet Bub; José Mauro Kutner; Lilian Castilho
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

8.  It's time to phase out "serologic weak D phenotype" and resolve D types with RHD genotyping including weak D type 4.

Authors:  Willy A Flegel; Gregory A Denomme; John T Queenan; Susan T Johnson; Margaret A Keller; Connie M Westhoff; Louis M Katz; Meghan Delaney; Ralph R Vassallo; Clayton D Simon; S Gerald Sandler
Journal:  Transfusion       Date:  2020-03-12       Impact factor: 3.337

9.  Testing for Partial RhD with a D-Screen Diagast Kit in Moroccan Blood Donors with Weak D Expression.

Authors:  Z Kabiri; M Benajiba; K Hajjout; N Dakka; H Bellaoui
Journal:  J Blood Transfus       Date:  2014-10-28

10.  Molecular basis of DEL phenotype in the Chinese population.

Authors:  Juan Gu; Xue-Dong Wang; Chao-Peng Shao; Jun Wang; An-Yuan Sun; Li-Hua Huang; Zhao-Lin Pan
Journal:  BMC Med Genet       Date:  2014-05-05       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.